Eisai (TSE:4523) Valuation and LEQEMBI Growth Outlook
- (TSE:4523) is seeing a reassessment of its market valuation following a recent decline in share price, as investors weigh the growth potential of its Alzheimer’s therapy, Leqembi, against...
- The stock has experienced a decline of approximately 9% over the past month and a year-to-date return of roughly 2% decline.
- According to analysis from Simply Wall St, the current share price sits below a narrative fair value of ¥5,009.
Eisai Co., Ltd. (TSE:4523) is seeing a reassessment of its market valuation following a recent decline in share price, as investors weigh the growth potential of its Alzheimer’s therapy, Leqembi, against short-term momentum losses.
As of May 9, 2026, Eisai shares were trading at ¥4,677. The stock has experienced a decline of approximately 9% over the past month and a year-to-date return of roughly 2% decline. However, the company’s one-year total shareholder return remains near 19%, and it has seen a gain of roughly 4% over the past three months.
According to analysis from Simply Wall St, the current share price sits below a narrative fair value of ¥5,009. This gap indicates a flagged intrinsic discount of about 30%, with the stock assigned a value score of 2.
The investment narrative for the pharmaceutical company is increasingly anchored by the performance of Leqembi. For the 2025 fiscal year, Leqembi generated ¥88 billion in revenue. The company reported preliminary sales of ¥26.2 billion for the first quarter of 2026.
Global Expansion and Market Penetration
Eisai is pursuing a durable, long-term revenue growth strategy through the international rollout of Leqembi. The company has executed launches in Japan and China and is currently making preparations for entry into European markets.
This expansion is targeted at regions with high unmet medical needs, driven by rising dementia prevalence and demographic shifts toward aging populations.
Regulatory Catalysts and Future Projections
A significant near-term catalyst for the company is the pending regulatory decision regarding the administration of its therapy. The U.S. Food and Drug Administration has accepted a supplemental Biologics License Application (BLA) for the IQLIK subcutaneous autoinjector for Leqembi.
The Prescription Drug User Fee Act (PDUFA) target date for this application is May 24, 2026. Approval of the autoinjector could accelerate the transition to at-home dosing, which may influence investor interpretations of the revenue run rate by improving patient convenience and adherence.
Long-term financial projections suggest significant scaling of the company’s operations. Current narratives project that Eisai will reach ¥938.2 billion in revenue and ¥74.9 billion in earnings by 2029.
While the company’s neuroscience focus is heavily concentrated on this single high-impact therapy, analysts are incorporating steady top-line expansion and firmer margins into their valuations as the drug penetrates new geographies.